ABVC Stock Summary and Trading Ideas (Abvc Biopharma | NASDAQ:ABVC)

ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Abvc Biopharma trades on the NASDAQ stock market under the symbol ABVC.

As of September 25, 2023, ABVC stock price climbed to $0.94 with 40,091 million shares trading.

ABVC has a beta of 1.00, meaning it tends to be less sensitive to market movements. ABVC has a correlation of 0.04 to the broad based SPY ETF.

ABVC has a market cap of $3.71 million. This is considered a Sub-Micro Cap stock.

Last quarter Abvc Biopharma reported $6,109 in Revenue and -$.68 earnings per share. This fell short of revenue expectation by $-293,891 and missed earnings estimates by -$.08.

The top ETF exchange traded funds that ABVC belongs to (by Net Assets): VTI, VXF.

ABVC has underperformed the market in the last year with a price return of -88.4% while the SPY ETF gained +17.2%. ABVC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.6% and -14.5%, respectively, while the SPY returned -0.6% and -2.6%, respectively.

ABVC support price is $.80 and resistance is $.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVC stock will trade within this expected range on the day.